SLC17A1 Antibody

What is SLC17A1 and why is it a significant research target?

SLC17A1 (Solute Carrier Family 17 Member 1) is a critical transmembrane protein primarily functioning as a sodium-dependent phosphate transporter in the kidney. It plays essential roles in phosphate homeostasis and organic anion transport, including urate excretion . SLC17A1 has gained significant research interest due to its established genetic associations with gout and hyperuricemia , and more recently, its identification as a key transporter for Lac-Phe (N-lactoyl-phenylalanine), a molecule involved in exercise-induced metabolic benefits . The protein is predominantly expressed in the apical membrane of renal proximal tubular cells, where it mediates the active transport of phosphate and various organic anions .

How do I choose between monoclonal and polyclonal SLC17A1 antibodies for my research?

The choice between monoclonal and polyclonal SLC17A1 antibodies depends on your specific research requirements:

Polyclonal antibodies (available from multiple vendors ) recognize multiple epitopes on SLC17A1 and typically offer:

• Higher sensitivity for detecting low-abundance SLC17A1 expression

• Greater tolerance to minor protein denaturation or conformational changes

• Broader reactivity across species (many available with human, mouse, and rat reactivity )

Monoclonal antibodies (such as clone 4B4D1 ) provide:

• Consistent lot-to-lot reproducibility for longitudinal studies

• Higher specificity for a single epitope, reducing cross-reactivity concerns

• Optimal for distinguishing between closely related SLC17 family members

• Preferred for quantitative comparative studies

For initial characterization studies, a polyclonal antibody might be preferable, while for specific epitope detection or quantitative analyses, a monoclonal antibody would be more suitable .

What are the recommended applications for SLC17A1 antibodies?

Based on validated research applications, SLC17A1 antibodies are primarily optimized for:

• Western Blotting (WB): Most commercial SLC17A1 antibodies are validated for WB , with recommended dilutions typically ranging from 1:500 to 1:2000. SLC17A1 is detected at approximately 50-64 kDa, depending on post-translational modifications and glycosylation status .

• Enzyme-Linked Immunosorbent Assay (ELISA): Many SLC17A1 antibodies are suitable for ELISA applications , providing quantitative measurement of SLC17A1 expression levels.

• Immunohistochemistry (IHC): Select antibodies are validated for IHC , allowing for visualization of SLC17A1 localization in tissue sections, particularly in kidney tissues.

• Immunofluorescence: Some antibodies are specifically validated for immunofluorescence applications , enabling subcellular localization studies of SLC17A1.

Always verify the specific application validation for your selected antibody and optimize protocols according to the manufacturer's recommendations .

What are the critical considerations for successful Western blotting with SLC17A1 antibodies?

For optimal Western blot detection of SLC17A1, consider the following methodological aspects:

• Sample preparation:

  • Kidney tissue lysates or transfected cells expressing SLC17A1 are preferred sample sources

  • Use lysis buffers containing 10% SDS with protease inhibitor cocktails to prevent degradation

  • Sonication of samples (25 impulses at 60% amplitude) improves protein extraction of this membrane protein

• Protein denaturation:

  • Extended denaturation at moderate temperature (56°C for 60 minutes) rather than brief boiling is recommended for this membrane protein

• Gel electrophoresis:

  • Use 10% separating gels with 5% focusing gels for optimal resolution

  • The predicted molecular weight is 51 kDa, but observed bands typically appear at 50-64 kDa due to post-translational modifications

• Antibody dilution and incubation:

  • Optimal dilutions range from 1:500-1:2000 depending on the specific antibody

  • Overnight incubation at 4°C with primary antibody generally yields better results than shorter incubations

• Blocking conditions:

  • 5% non-fat milk for 1.5 hours has been validated for effective blocking

How can I validate the specificity of my SLC17A1 antibody?

Rigorous validation of SLC17A1 antibody specificity is crucial for reliable research outcomes:

• Positive and negative controls:

  • Positive controls: Human or mouse kidney tissues/lysates express high levels of SLC17A1

  • Negative controls: Tissues known to have minimal SLC17A1 expression or SLC17A1 knockout models

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide; specific signal should be substantially reduced

• Overexpression systems:

  • Compare signal in cells transfected with SLC17A1 expression constructs versus empty vector controls

• Knockdown/knockout validation:

  • Use CRISPR/Cas9-mediated SLC17A1 knockout cells or tissues from knockout mice to confirm signal specificity

  • SLC17A1 knockout TKPTS cells have been reported as valuable negative controls

• Cross-reactivity assessment:

  • Test for potential cross-reactivity with other SLC17 family members, particularly SLC17A2, SLC17A3, and SLC17A4, which share sequence homology

What are the key considerations for analyzing SLC17A1 expression in different species?

When studying SLC17A1 across species, consider these important factors:

• Species-specific reactivity:

  • Antibody reactivity varies across species - verify the validated reactivity claims for your research model

  • Some antibodies are specifically optimized for human samples , while others offer broader reactivity including mouse, rat, cow, horse, and other mammals

• Sequence homology considerations:

  • Sequence homology across species varies: human-horse (100%), human-cow (85%), human-dog (83%), human-pig (77%)

  • For cross-species applications, select antibodies targeting highly conserved epitopes

• Molecular weight variations:

  • Expect slight variations in molecular weight across species due to differences in amino acid sequence and post-translational modifications

  • Human SLC17A1 appears at approximately 50-51 kDa, while mouse SLC17A1 may exhibit slight size differences

• Expression pattern differences:

  • While predominantly expressed in kidney across species, the relative expression levels in other tissues may vary between species

  • Consider species-specific expression patterns when designing experiments

How can SLC17A1 antibodies be utilized to study SLC17A1's role in urate transport and gout pathophysiology?

For investigating SLC17A1's role in urate transport and gout:

• Tissue expression profiling:

  • Use validated SLC17A1 antibodies to quantify expression levels in kidney samples from gout patients versus healthy controls

  • Immunohistochemistry can localize SLC17A1 in specific nephron segments to correlate with urate handling capacities

• Genetic variant functional analysis:

  • Combine SNP analysis with antibody-based protein expression studies to assess how variants like rs9461218 in the SLC17A1 gene affect protein expression levels and localization

  • Investigate protein expression changes in cells expressing known SLC17A1 variants associated with hyperuricemia

• Transport activity correlation:

  • Correlate SLC17A1 protein levels (detected by immunoblotting) with urate transport activity in cellular models

  • Measure urate efflux in cells with varying SLC17A1 expression levels, as confirmed by antibody detection

• Pharmacological intervention studies:

  • Use SLC17A1 antibodies to monitor protein expression changes in response to uricosuric drugs

  • Compare SLC17A1 expression levels in animal models before and after treatment with compounds that modulate urate handling

• Co-localization studies:

  • Perform dual immunofluorescence with SLC17A1 antibodies and other transporters involved in urate handling to understand their spatial relationships in renal tubules

What approaches can be used to study SLC17A1's newly discovered role in Lac-Phe transport?

To investigate SLC17A1's role in Lac-Phe transport, recently identified as significant :

What are the optimal approaches for distinguishing between SLC17A1 and other closely related SLC17 family members?

Differentiating between SLC17 family members requires careful methodological considerations:

• Epitope-specific antibody selection:

  • Choose antibodies targeting unique regions that differ between SLC17A1, SLC17A2, SLC17A3, and SLC17A4

  • Antibodies targeting N-terminal or C-terminal regions often provide better specificity than those targeting conserved transmembrane domains

• Expression pattern analysis:

  • Leverage tissue-specific expression patterns: SLC17A1 is predominantly expressed in kidney, while other family members show different tissue distributions

  • Use tissue microarrays with parallel antibody staining to create expression profiles for each transporter

• Verification with recombinant proteins:

  • Use purified recombinant proteins of each SLC17 family member to validate antibody specificity through Western blotting

  • Quantify cross-reactivity percentages to understand potential false-positive signals

• Knockout/knockdown controls:

  • Implement siRNA knockdowns or CRISPR knockouts specific to each family member and confirm specificity with the respective antibodies

  • Expression of each transporter should be individually verified, as demonstrated in studies of SLC17A1-4 mRNA expression

• Combined DNA and protein analyses:

  • Correlate antibody-detected protein levels with qPCR measurements of each family member's mRNA

  • This dual verification approach helps confirm that the detected protein corresponds to the appropriate transcript

What are common issues with SLC17A1 antibody performance and how can they be addressed?

Common challenges with SLC17A1 antibodies and their solutions include:

• Multiple bands in Western blot:

  • Cause: Post-translational modifications, glycosylation variants, or degradation products

  • Solution: Use fresh samples with complete protease inhibitors; compare with positive control samples; consider different antibodies targeting different epitopes

• Weak or no signal:

  • Cause: Low endogenous expression, inefficient protein extraction, or antibody sensitivity issues

  • Solution: Use kidney tissue as positive control; optimize membrane protein extraction protocols; consider longer exposure times or more sensitive detection methods

• Non-specific background:

  • Cause: Insufficient blocking or antibody cross-reactivity

  • Solution: Increase blocking time (up to 1.5 hours) with 5% milk; optimize antibody dilution; try alternative blocking agents like BSA if using phospho-specific antibodies

• Inconsistency between biological replicates:

  • Cause: Variable extraction efficiency or protein degradation

  • Solution: Standardize sample collection and processing; quantify total protein and adjust loading accordingly; use internal loading controls consistently

• Detection in unexpected molecular weight ranges:

  • Cause: Alternative splicing, proteolytic processing, or post-translational modifications

  • Solution: Validate with recombinant protein controls; use multiple antibodies targeting different epitopes; verify with mass spectrometry if possible

How can I optimize immunoprecipitation protocols using SLC17A1 antibodies?

For successful immunoprecipitation (IP) of SLC17A1:

• Extraction buffer optimization:

  • Use mild detergents (1% Triton X-100, 0.5% NP-40) to solubilize membrane proteins while maintaining native conformation

  • Include phosphatase inhibitors if studying phosphorylation status of SLC17A1

• Pre-clearing samples:

  • Pre-clear lysates with Protein A/G beads to reduce non-specific binding

  • This step is particularly important when working with kidney tissue lysates that contain abundant proteins

• Antibody selection and amount:

  • Choose antibodies specifically validated for IP applications

  • Typically use 2-5 μg of antibody per 500 μg of total protein for optimal results

  • Consider using antibodies targeting exposed epitopes rather than transmembrane regions

• Incubation conditions:

  • Extended incubation (overnight at 4°C) with gentle rotation improves capture efficiency

  • Maintain consistent temperature to preserve protein-antibody interactions

• Washing stringency balance:

  • Use gradually increasing salt concentrations in wash buffers to reduce background while maintaining specific interactions

  • Typically start with low stringency (150 mM NaCl) and increase to medium stringency (300 mM NaCl) in subsequent washes

What strategies can improve the detection of SLC17A1 in challenging tissue samples?

For enhancing SLC17A1 detection in difficult samples:

• Antigen retrieval optimization:

  • For formalin-fixed tissues, optimize antigen retrieval conditions (pH 6.0 citrate buffer or pH 9.0 Tris-EDTA)

  • Heat-induced epitope retrieval (HIER) may be necessary to expose epitopes masked during fixation

• Signal amplification methods:

  • Implement tyramide signal amplification (TSA) for immunohistochemistry to enhance sensitivity

  • Consider using more sensitive detection systems like SuperSignal West Femto for Western blotting of low-abundance samples

• Enrichment of membrane fractions:

  • Use differential centrifugation to isolate membrane fractions where SLC17A1 is concentrated

  • Employ sucrose gradient ultracentrifugation for further purification of plasma membrane fractions

• Alternative fixation methods:

  • For immunofluorescence, compare paraformaldehyde with other fixatives like methanol or acetone

  • Some epitopes may be better preserved with specific fixation protocols

• Co-localization with known markers:

  • Use dual labeling with established kidney proximal tubule markers to help identify regions where SLC17A1 should be present

  • This approach can help distinguish true signal from background in complex tissue samples

How can SLC17A1 antibodies contribute to research on exercise metabolism and Lac-Phe signaling?

SLC17A1 antibodies can advance exercise metabolism research through:

• Exercise-induced expression changes:

  • Quantify changes in SLC17A1 protein levels in response to different exercise regimens using validated antibodies

  • Compare acute versus chronic exercise effects on SLC17A1 expression and localization

• Tissue-specific regulation:

  • Map SLC17A1 expression across tissues involved in exercise metabolism

  • Correlate expression levels with Lac-Phe transport capacity and metabolic outcomes

• Mechanistic pathway studies:

  • Investigate co-regulation of SLC17A1 with CNDP2 (the Lac-Phe biosynthetic enzyme) during exercise

  • Use proximity ligation assays with SLC17A1 antibodies to detect potential protein-protein interactions with metabolic regulators

• Genetic variant functional impacts:

  • Correlate SNPs associated with altered Lac-Phe levels (like rs9461218) with SLC17A1 protein expression or subcellular localization

  • Implement immunoprecipitation followed by mass spectrometry to identify exercise-responsive SLC17A1 interactors

• Therapeutic intervention monitoring:

  • Use SLC17A1 antibodies to track changes in expression or localization in response to exercise mimetics or metabolic modulators

  • This approach could validate SLC17A1 as a potential therapeutic target for metabolic diseases

What is the potential for using SLC17A1 antibodies in studying drug transport and drug-drug interactions?

SLC17A1 antibodies offer valuable tools for drug transport research:

• Drug-induced regulation studies:

  • Monitor changes in SLC17A1 expression in response to drug treatments using quantitative immunoblotting

  • Compare membrane versus intracellular protein levels to detect trafficking changes

• Structure-function analysis:

  • Epitope mapping using different SLC17A1 antibodies can provide insights into conformational changes induced by drug binding

  • This approach complements transport activity measurements to understand structural determinants of drug recognition

• Drug competition assessment:

  • Combine SLC17A1 antibody-based protein quantification with functional transport assays to correlate expression levels with transport capacity for different drugs

  • Investigate how drugs like salicylate, aspirin, and others compete with urate transport, as shown in the inhibition table below :

• Transporter complex formation:

  • Use co-immunoprecipitation with SLC17A1 antibodies to identify potential interacting proteins that might influence drug transport

  • Investigate whether drug binding alters these protein-protein interactions

• Clinical sample analysis:

  • Apply validated SLC17A1 antibodies to analyze kidney biopsy samples from patients experiencing drug-induced nephrotoxicity

  • Correlate SLC17A1 expression levels with drug disposition and adverse events

How can SLC17A1 antibodies be utilized in combination with emerging technologies for transporter research?

Integration of SLC17A1 antibodies with cutting-edge methodologies offers powerful new research possibilities:

• Proximity labeling approaches:

  • Combine SLC17A1 antibodies with BioID or APEX2 proximity labeling to identify the SLC17A1 interactome

  • This approach can reveal previously unknown protein partners that regulate transporter function or localization

• Super-resolution microscopy:

  • Apply validated SLC17A1 antibodies with techniques like STORM or PALM to visualize nanoscale distribution of transporters in the membrane

  • These approaches can reveal potential transporter clustering or segregation into functional domains

• Live-cell imaging adaptations:

  • Develop nanobody derivatives from conventional SLC17A1 antibodies that can be used for live-cell studies

  • These smaller antibody fragments enable real-time tracking of SLC17A1 trafficking and dynamics

• Single-cell analysis integration:

  • Combine flow cytometry or mass cytometry (CyTOF) with SLC17A1 antibodies to profile transporter expression at single-cell resolution

  • This approach can reveal cellular heterogeneity in transporter expression within tissues

• Organ-on-chip applications:

  • Validate SLC17A1 antibodies for immunofluorescence in kidney-on-chip models to study transporter function under physiological flow conditions

  • These models enable dynamic assessment of transporter regulation and drug interactions in a more physiologically relevant context